Activation of α2-adrenergic receptors triggers tumour immune rejection.

Activation of α2-adrenergic receptors triggers tumor immune rejection, according to a study published in Nature. The researchers found that activation of these receptors on immune cells led to increased tumor infiltration and improved anti-tumor immune responses in mice. The study suggests that targeting adrenergic receptors could be a promising approach for cancer immunotherapy. Additionally, the study highlights the importance of neuro-immune interactions in cancer and the potential of beta blockers to improve the efficacy of immunotherapies.